COVID-19 Infections in MS & Related Diseases
The COViMS (COVID-19 Infections in MS & Related Diseases) registry is a joint effort of the National MS Society, the Consortium of MS Centers and the Multiple Sclerosis Society of Canada.
The objective of the registry is to define the impact of COVID-19 on patients with MS and other CNS demyelinating diseases (Neuromyelitis Optica Spectrum Disease, or MOG antibody disease) who have developed COVID-19.
Overview
- Acronym
- COViMS
- Website
- COViMS
- Investigators
-
- Contacts
-
General Design
- Study design
- Registry
- Start - End Year
- 2020 - 2022
- Recruitment Target
-
- Individuals
- Number of Participants
- 5,208
- Supplementary information about number of participants
-
* 4602 participants had a positive laboratory result. * 606 participants were suspected but not confirmed positive cases.
- Supplementary Information
-
* To enable ease of information sharing, COViMS Registry data collection was harmonized with the Global Data Sharing ini-tiative acquiring information on SARS-CoV-2 infection world-wide. * This registry has been determined "not human subjects research" under US Federal Guidelines by the IRB at Washington University in St. Louis. The database contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Summary data is provided through the COViMS website.
- On the study website : https://www.covims.org/
Marker Papers
Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021 Jun 1;78(6):699-708. doi: 10.1001/jamaneurol.2021.0688. Erratum in: JAMA Neurol. 2021 Jun 1;78(6):765.
PUBMED 33739362Newsome SD, Cross AH, Fox RJ, et al. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry. Neurol Neuroimmunol Neuroinflamm. 2021 Aug 24;8(5):e1057. doi: 10.1212/NXI.0000000000001057.
PUBMED 34429342Timeline
Population
COViMS population
The population is composed of patients with multiple sclerosis and related diseases who had laboratory-positive for SARS-CoV-2 or are highly suspected to be infected with SARS-CoV-2.
Selection Criteria
- Countries
-
- Canada
- United States of America
- Mexico
- Canadian Provinces
-
- Alberta
- British Columbia
- Manitoba
- New Brunswick
- Newfoundland and Labrador
- Northwest Territories
- Nova Scotia
- Nunavut
- Ontario
- Prince Edward Island
- Quebec
- Saskatchewan
- Yukon
- Health Status
-
- Inclusion criteria : * Patients with multiple sclerosis and related diseases. * Laboratory confirmed COVID patients. * Suspected COVID-19 patients but not confirmed who have fever with following symptoms or diseases; Dry cough, +/- anorexia, myalgias, dyspnea, anosmia/ageusia and potential exposure.
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Health care providers were asked to report patients for SARS-CoV-2 infection after a minimum of 7 days from initial infectious symptom onset and when sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death.
Sample Size
- Number of Participants
- 5,208
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | COViMS - Database |
|
2020 (April) | Ongoing |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-05-16T18:51:42.100